GET DAILY SIGNALSWhat Daré Bioscience (DARE) Earnings Could Reveal About Its Commercial Strategy
Key Takeaways
- Daré Bioscience is expected to report its third-quarter 2026 results (quarter ended September 30, 2026) in mid-November 2026.
- Consensus estimates point to a loss of roughly -$0.14 per share on revenue near $2.0 million, though analyst coverage remains limited for this pre-commercial-stage biotech.
- This quarter marks the first period in which revenue from the Flora Sync LF5 probiotic launch and early DARE to PLAY (Sildenafil Cream) dispensing is expected to be recorded.
- Liquidity and going-concern considerations stay in focus after Q2 2026 ended with approximately $12.6 million in cash and a modest working capital deficit.
- Investors will also watch for updates on the Ovaprene Phase 3 contraceptive study, which recently reported positive interim data.
- For more context on this ticker, review its Major News, Today's Price Move, Price Targets, and Forecast pages.
- You can also explore Trending AI Robots for additional trading ideas and signal-driven insights.
Earnings Context and Why It Matters
Daré Bioscience is a women's health biopharmaceutical company that has spent years advancing a pipeline of product candidates, from the FDA-approved XACIATO bacterial vaginosis gel to the investigational Ovaprene contraceptive. More recently, management shifted toward a "dual-path" strategy that pairs traditional regulatory development with faster-to-market commercialization through compounding channels. The upcoming Q3 2026 report is significant because it should offer the first tangible read on that commercial pivot: sales from the Flora Sync LF5 vaginal probiotic, which launched in June 2026, and early prescription activity for DARE to PLAY. For a company still reporting net losses, evidence of real product revenue and disciplined expense management will shape how investors assess its path toward sustainability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Analyst estimates for Daré Bioscience's third quarter of fiscal 2026 remain limited, reflecting the company's small float and early commercial stage. Consensus expectations point to a loss of roughly -$0.14 per share, with revenue forecast near $2.0 million, according to aggregated estimates. By comparison, the company reported a net loss of -$0.20 per share on revenue of approximately $187,550 in Q2 2026, and essentially negligible revenue of about $2,260 in the year-ago Q3 2025 period.
Because Daré Bioscience has historically generated little top-line revenue, the most important metrics will extend beyond EPS (earnings per share). Investors will focus on the initial recorded sales contribution from Flora Sync LF5, early prescription trends for DARE to PLAY, R&D (research and development) expense levels, and the company's cash balance and runway. Management commentary on commercialization progress and any update to its capital-raising plans will carry particular weight.
Market Reaction and Investor Sentiment
Sentiment heading into the Q3 2026 report is cautiously mixed. Daré Bioscience shares have experienced meaningful volatility in 2026, reflecting both enthusiasm around the company's first direct-to-market product launches and persistent concerns about liquidity and capital needs. The company disclosed in recent filings that it had substantial doubt about its ability to continue as a going concern, and it has been subject to Nasdaq listing compliance monitoring. As a result, the market's reaction will likely hinge less on the headline loss and more on two questions: whether early product sales demonstrate genuine commercial traction, and whether management can articulate a credible path to funding its operations without excessive dilution. Any setbacks in launch execution, enrollment delays in the Ovaprene Phase 3 study, or signs of faster-than-expected cash burn could weigh on the stock.
Forward Outlook and Key Factors to Monitor
The central question for Daré Bioscience after this earnings event is whether it can build a sustainable, multi-product revenue stream. Flora Sync LF5, the company's first directly commercialized product, began generating sales in July 2026, and investors will be watching for sequential growth into subsequent quarters. Similarly, DARE to PLAY, a sildenafil cream targeting female sexual arousal disorder (FSAD), was expected to begin prescription dispensing in Q3 2026, with management pointing to a substantial addressable market.
Beyond commercialization, the clinical pipeline remains a key catalyst. Ovaprene, a hormone-free monthly contraceptive, is in a pivotal Phase 3 trial, and interim results were positive enough for an independent data monitoring board to recommend continuing the study without modification. Topline data is expected in 2027. DARE-HPV and DARE-LARC1 programs continue to benefit from non-dilutive grant funding, which helps offset R&D costs.
Financially, investors should monitor cash balances, the deferred grant liability, and any new capital raises. The company has indicated it will need additional funding to sustain operations, and the terms of future financing will matter for existing shareholders. Regulatory and listing compliance, including Nasdaq requirements, also remain on the watchlist. While the commercial pivot is a meaningful step, the durability of early sales and the pace of clinical progress will ultimately determine whether Daré Bioscience can narrow losses and move toward self-sufficiency.
How Tickeron’s AI Screener Fits Into My Process
When evaluating small-cap names like this one, I often turn to Tickeron’s AI Screener to quickly filter for comparable healthcare stocks and spot emerging technical or fundamental signals. It helps me place the current setup in broader context without spending hours on manual screens, which keeps my analysis focused on the metrics that matter most for this earnings release.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DARE's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for DARE turned positive on October 30, 2026. Looking at past instances where DARE's MACD turned positive, the stock continued to rise in 31 of 40 cases over the following month. The odds of a continued upward trend are 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where DARE's RSI Oscillator exited the oversold zone, 28 of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 63 cases where DARE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
Following a +2.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where DARE advanced for three days, in 165 of 219 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DARE as a result. In 76 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DARE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for DARE entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-22.504) is normal, around the industry mean (3.498). P/E Ratio (-0.972) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (7.502) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. DARE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DARE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of pharmaceutical products
Industry Biotechnology
Advertisement